Cancer Research and Treatment

Original Articles

Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30–Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial: Seok Jin Kim, Dok Hyun Yoon, Jin Seok Kim, Hye Jin Kang, Hye Won Lee, Hyeon-Seok Eom, Jung Yong Hong, Junhun Cho, Young Hyeh Ko, Jooryung Huh, Woo-Ick Yang, Weon Seo Park, Seung-Sook Lee, Cheolwon Suh, Won Seog Kim; Cancer Res Treat. 2020;52(2):374-387. Published online August 13, 2019; DOI: https://doi.org/10.4143/crt.2019.198

Purpose
The treatment outcome of brentuximab vedotin (BV) has not been related with CD30 expression in previous studies enrolling patients with a wide range of CD30 expression level. Thus, this study explored the efficacy of BV in high-CD30–expressing non-Hodgkin lymphoma (NHL) patients most likely to benefit.
Materials and Methods
This phase II study (Clinicaltrials.gov: NCT02280785) enrolled relapsed or refractory high-CD30–expressing NHL, with BV administered intravenously at 1.8 mg/kg every 3 weeks. The primary endpoint was > 40% disease control rate, consisting of complete response (CR), partial response (PR), or stable disease. We defined high CD30 expression as ≥ 30% tumor cells positive for CD30 by immunohistochemistry.
Results
High-CD30-expressing NHL patients (n=33) were enrolled except anaplastic large cell lymphoma. The disease control rate was 48.5% (16/33) including six CR and six PR; six patients (4CR, 2PR) maintained their response over 16 completed cycles. Response to BV and survival were not associated with CD30 expression levels. Over a median of 29.2 months of follow-up, the median progression-free and overall survival rates were 1.9 months and 6.1 months, respectively. The most common adverse events were fever (39%), neutropenia (30%), fatigue (24%), and peripheral sensory neuropathy (27%). In a post-hoc analysis for the association of multiple myeloma oncogene 1 (MUM1) on treatment outcome, MUM1- negative patients showed a higher response (55.6%, 5/9) than MUM1-positive patients (13.3%, 2/15).
Conclusion
BV performance as a single agent was acceptable in terms of disease control rates and toxicity profiles, especially MUM1-negative patients.

Citations

Citations to this article as recorded by

Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review
Mohammad Sadegh Fallahi, Nasibeh Zerangian, Atousa Ghorbani, Gisou Erabi, Melika Shirali, Elaheh Shabani, Foad Rommasi, Mahsa Mohammadi Najafabadi, Shima Karbasi, Samaneh Toutounchian, Ramin Ahangar-Sirous, Ava Motaghy, Mahsa Heidari, Niloofar Deravi
Current Cancer Therapy Reviews.2024; 20(1): 53. CrossRef
Phase I/II clinical trial of brentuximab vedotin for pretreated Japanese patients with CD30‐positive cutaneous T‐cell lymphoma
Yoji Hirai, Jun Sakurai, Shiho Yoshida, Takashi Kikuchi, Toshiharu Mitsuhashi, Tomoko Miyake, Taku Fujimura, Riichiro Abe, Hiroki Fujikawa, Hikari Boki, Hiraku Suga, Sayaka Shibata, Tomomitsu Miyagaki, Takatoshi Shimauchi, Eiji Kiyohara, Yoshio Kawakami,
The Journal of Dermatology.2024; 51(8): 1037. CrossRef
Brentuximab vedotin therapy followed by autologous peripheral stem cell transplantation as a viable treatment option for an older adult with transformed lymphoma: a case report and literature review
Jiewen Tan, Jinman Zhong, Wanzhen Hu, Guobiao Wu, Chong Zeng, Dan Xiong
Journal of International Medical Research.2024;[Epub] CrossRef
Belantamab mafodotin concentration–QTc relationships in patients with relapsed or refractory multiple myeloma from the DREAMM‐1 and ‐2 studies
Roxanne C. Jewell, Richard J. Mills, Colm Farrell, Sandra A. G. Visser
British Journal of Clinical Pharmacology.2024;[Epub] CrossRef
Resistance mechanisms and potential therapeutic strategies in relapsed or refractory natural killer/T cell lymphoma
Chengji Wang, Liang Wang
Chinese Medical Journal.2024; 137(19): 2308. CrossRef
Research progress on EBV-associated NK/T cell lymphoma
Jun CAI, Yi CAO, LiYun QIU, Yan GAO, HuiQiang HUANG, QingQing CAI
SCIENTIA SINICA Vitae.2024; 54(12): 2363. CrossRef
Treatment of extranodal NK/T-cell lymphoma: From past to future
Zheng Yan, Shuna Yao, Zhizhong Wang, Wenping Zhou, Zhihua Yao, Yanyan Liu
Frontiers in Immunology.2023;[Epub] CrossRef
Rational Targets of Therapy in Extranodal NK/T-Cell Lymphoma
Ajay Major, Pierluigi Porcu, Bradley M. Haverkos
Cancers.2023; 15(5): 1366. CrossRef
Safety of Concurrent Radiation Therapy With Brentuximab Vedotin in the Treatment of Lymphoma
Susan Y. Wu, Penny Q. Fang, Ethan B. Wang, Sairah Ahmed, Madeleine Duvic, Preetesh Jain, Luis E. Malpica Castillo, Ranjit Nair, Raphael E. Steiner, Paolo Strati, Auris O. Huen, Swaminathan P. Iyer, Chelsea C. Pinnix, Bouthaina S. Dabaja, Jillian R. Gunthe
Advances in Radiation Oncology.2023; 8(6): 101279. CrossRef
Novel target and treatment agents for natural killer/T-cell lymphoma
Xiao-Peng Tian, Yi Cao, Jun Cai, Yu-Chen Zhang, Qi-Hua Zou, Jin-Ni Wang, Yu Fang, Jia-Hui Wang, Song-Bin Guo, Qing-Qing Cai
Journal of Hematology & Oncology.2023;[Epub] CrossRef
Treatment‐related adverse events of antibody‐drug conjugates in clinical trials: A systematic review and meta‐analysis
Jinming Li, Guoshuang Shen, Zhen Liu, Yaobang Liu, Miaozhou Wang, Fuxing Zhao, Dengfeng Ren, Qiqi Xie, Zitao Li, Zhilin Liu, Yi Zhao, Fei Ma, Xinlan Liu, Zhengbo Xu, Jiuda Zhao
Cancer Innovation.2023; 2(5): 346. CrossRef
Advances and challenges of immunotherapies in NK/T cell lymphomas
Ling He, Na Chen, Lei Dai, Xingchen Peng
iScience.2023; 26(11): 108192. CrossRef
Brentuximab vedotin in treating Chinese patients with lymphoma: A multicenter, real‐world study
Xudong Zhang, Honghan Qiao, Xiaofei Chai, Xue Gao, Rongjun Ma, Yufu Li, Zunmin Zhu, Mingzhi Zhang
Cancer Medicine.2023; 12(24): 21725. CrossRef
A multi-center and non-interventional registry of brentuximab vedotin in patients with relapsed or refractory CD30-positive lymphoma: the CISL1803/BRAVO study
Seok Jin Kim, Young Rok Do, Ho-Sup Lee, Won-Sik Lee, Jee Hyun Kong, Jae-Yong Kwak, Hyeon-Seok Eom, Joon Ho Moon, Jun Ho Yi, Jeong-Ok Lee, Jae-Cheol Jo, Deok-Hwan Yang
Blood Research.2023; 58(4): 194. CrossRef
Update on Molecular Diagnosis in Extranodal NK/T-Cell Lymphoma and Its Role in the Era of Personalized Medicine
Ka-Hei (Murphy) Sun, Yin-Ting (Heylie) Wong, Ka-Man (Carmen) Cheung, Carmen (Michelle) Yuen, Yun-Tat (Ted) Chan, Wing-Yan (Jennifer) Lai, Chun (David) Chao, Wing-Sum (Katie) Fan, Yuen-Kiu (Karen) Chow, Man-Fai Law, Ho-Chi (Tommy) Tam
Diagnostics.2022; 12(2): 409. CrossRef
Phase 1/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma
Jeffrey P. Ward, Melissa M. Berrien-Elliott, Felicia Gomez, Jingqin Luo, Michelle Becker-Hapak, Amanda F. Cashen, Nina D. Wagner-Johnston, Kami Maddocks, Matthew Mosior, Mark Foster, Kilannin Krysiak, Alina Schmidt, Zachary L. Skidmore, Sweta Desai, Marcu
Blood.2022; 139(13): 1999. CrossRef
Monoclonal Antibodies in the Treatment of Diffuse Large B-Cell Lymphoma: Moving beyond Rituximab
Sotirios G. Papageorgiou, Thomas P. Thomopoulos, Athanasios Liaskas, Theodoros P. Vassilakopoulos
Cancers.2022; 14(8): 1917. CrossRef
Basic immunohistochemistry for lymphoma diagnosis
Junhun Cho
Blood Research.2022; 57(S1): S55. CrossRef
Extranodal Natural Killer/T-Cell Lymphomas: Current Approaches and Future Directions
John C. Reneau, Polina Shindiapina, Zachary Braunstein, Youssef Youssef, Miguel Ruiz, Saira Farid, Walter Hanel, Jonathan E. Brammer
Journal of Clinical Medicine.2022; 11(10): 2699. CrossRef
CD30 + Primary intestinal T-cell lymphoma (unclassified) masquerading as chronic inflammation: a case report
Kashif Osmani, Eshana Shah, Bradley Drumheller, Shaun Webb, Manmeet Singh, Paul Rubinstein, John Patrick Galvin, Megan S. Lim, Carlos Murga-Zamalloa
Diagnostic Pathology.2022;[Epub] CrossRef
EBV-associated NK and T-cell lymphoid neoplasms
Hiroshi Kimura, Laurence de Leval, Qingqing Cai, Won Seog Kim
Current Opinion in Oncology.2022; 34(5): 422. CrossRef
Intravascular NK/T-Cell Lymphoma: What We Know about This Diagnostically Challenging, Aggressive Disease
Magda Zanelli, Paola Parente, Francesca Sanguedolce, Maurizio Zizzo, Andrea Palicelli, Alessandra Bisagni, Illuminato Carosi, Domenico Trombetta, Luca Mastracci, Linda Ricci, Saverio Pancetti, Giovanni Martino, Giuseppe Broggi, Rosario Caltabiano, Alberto
Cancers.2022; 14(21): 5458. CrossRef
Extranodal natural killer/T-cell lymphoma: An overview on pathology and clinical management
Eric Tse, Christopher P. Fox, Alexander Glover, Sang Eun Yoon, Won Seog Kim, Yok-Lam Kwong
Seminars in Hematology.2022; 59(4): 198. CrossRef
Primary Mediastinal B-Cell Lymphoma: Novel Precision Therapies and Future Directions
Huan Chen, Tao Pan, Yizi He, Ruolan Zeng, Yajun Li, Liming Yi, Hui Zang, Siwei Chen, Qintong Duan, Ling Xiao, Hui Zhou
Frontiers in Oncology.2021;[Epub] CrossRef
NK-/T-cell lymphomas
Hua Wang, Bi-bo Fu, Robert Peter Gale, Yang Liang
Leukemia.2021; 35(9): 2460. CrossRef
The landscape of new drugs in extranodal NK/T-cell lymphoma
Liang Wang, Lin-Rong Li, Luo Zhang, Jing-Wen Wang
Cancer Treatment Reviews.2020; 89: 102065. CrossRef
Molecular insights into pathogenesis and targeted therapy of peripheral T cell lymphoma
Caiqin Xie, Xian Li, Hui Zeng, Wenbin Qian
Experimental Hematology & Oncology.2020;[Epub] CrossRef
New agents and regimens for diffuse large B cell lymphoma
Liang Wang, Lin-rong Li, Ken H. Young
Journal of Hematology & Oncology.2020;[Epub] CrossRef
A Phase II Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive- and CD30-Positive Lymphomas
Miso Kim, Jeong-Ok Lee, Jiwon Koh, Tae Min Kim, Ji Yun Lee, Yoon Kyung Jeon, Bhumsuk Keam, Dong-Wan Kim, Jong Seok Lee, Dae Seog Heo
SSRN Electronic Journal .2020;[Epub] CrossRef

10,471 View
634 Download
29 Web of Science
29 Crossref

Identification of Significant Prognostic Tissue Markers Associated with Survival in Upper Urinary Tract Urothelial Carcinoma Patients Treated with Radical Nephroureterectomy: A Retrospective Immunohistochemical Analysis Using Tissue Microarray: Sung Han Kim, Weon Seo Park, Boram Park, Jinsoo Chung, Jae Young Joung, Kang Hyun Lee, Ho Kyung Seo; Cancer Res Treat. 2020;52(1):128-138. Published online June 19, 2019; DOI: https://doi.org/10.4143/crt.2019.119

Abstract PDF Supplementary Material PubReader ePub

Purpose
The purpose of this study was to identify prognostic tissue markers for several survival outcomes after radical nephroureterectomy among patients with upper urinary tract urothelial carcinoma using tissue microarray and immunohistochemistry.
Materials and Methods
Retrospectively, data of 162 non-metastatic patients with upper urinary tract urothelial carcinoma after radical nephroureterectomy between 2004 and 2016 were reviewed to determine intravesical recurrence-free survival (IVRFS), disease-free survival (DFS), and overall survival (OS). The expression of 27 tissue markers on a tissue microarray of radical nephroureterectomy samples and prognostic values of clinicopathological parameters were evaluated using immunohistochemistry and Cox proportional hazard models after adjusting for significant prognostic clinicopathological variables. The expression of all tissue markers was categorized into a binary group with continuous H-scores (0-300).
Results
Median follow-up was 53.4 months (range, 3.6 to 176.5 months); and, 58 (35.8%), 48 (29.6%), and 19 (11.7%) bladder recurrence, disease progression, and all cause death, respectively, were identified. After adjusting for significant clinicopathological factors including intravesical instillation for bladder recurrence-free survival, pathologic T category and intravesical instillation for disease progression-free survival , and pathologic T category for OS (p < 0.05), IVRFS was associated with epithelial cadherin (hazard ratio [HR], 0.49), epidermal growth factor receptor/erythroblastosis oncogene B (c-erb) (HR, 2.59), and retinoblastoma protein loss (HR, 1.85); DFS was associated with cyclin D1 (HR, 2.16) and high-molecular-weight cytokeratin (HR, 0.42); OS was associated with E-cadherin (HR, 0.34) and programmed cell death 1 ligand (HR, 13.42) (p < 0.05).
Conclusion
Several significant tissue markers were associated with survival outcomes in upper urinary tract urothelial carcinoma patients treated with radical nephroureterectomy.

Citations

Citations to this article as recorded by

A multi‐institutional retrospective study of open versus laparoscopic nephroureterectomy focused on the intravesical recurrence
Soichiro Shimura, Kazumasa Matsumoto, Masaomi Ikeda, Shigenori Moroo, Dai Koguchi, Yoshinori Taoka, Takahiro Hirayama, Yasukiyo Murakami, Takuji Utsunomiya, Daisuke Matsuda, Norihiko Okuno, Akira Irie, Masatsugu Iwamura
Asia-Pacific Journal of Clinical Oncology.2023; 19(1): 71. CrossRef
Upper Tract Urinary Carcinoma: A Unique Immuno-Molecular Entity and a Clinical Challenge in the Current Therapeutic Scenario
Giulia Mazzaschi, Giulia Claire Giudice, Matilde Corianò, Davide Campobasso, Fabiana Perrone, Michele Maffezzoli, Irene Testi, Luca Isella, Umberto Maestroni, Sebastiano Buti
Technology in Cancer Research & Treatment.2023;[Epub] CrossRef
Prognostic value of programmed death ligand‐1 and programmed death‐1 expression in patients with upper tract urothelial carcinoma
Luca Campedel, Eva Compérat, Géraldine Cancel‐Tassin, Justine Varinot, Christian Pfister, Clara Delcourt, Françoise Gobet, Mathieu Roumiguié, Pierre‐Marie Patard, Gwendoline Daniel, Pierre Bigot, Julie Carrouget, Caroline Eymerit, Stéphane Larré, Priscill
BJU International.2023; 132(5): 581. CrossRef
The Prevalence and Prognostic Role of PD-L1 in Upper Tract Urothelial Carcinoma Patients Underwent Radical Nephroureterectomy: A Systematic Review and Meta-Analysis
Yi Lu, Jiaqi Kang, Zhiwen Luo, Yuxuan Song, Jia Tian, Zhongjia Li, Xiao Wang, Li Liu, Yongjiao Yang, Xiaoqiang Liu
Frontiers in Oncology.2020;[Epub] CrossRef

7,348 View
142 Download
4 Web of Science
4 Crossref

Retrospective Study of the Significant Predictive Role of Inflammatory Degree in Initial and Repeat Prostate Biopsy Specimens for Detecting Prostate Cancer: Sung Han Kim, Boram Park, Jae Young Joung, Jinsoo Chung, Ho Kyung Seo, Kang Hyun Lee, Weon Seo Park; Cancer Res Treat. 2019;51(3):910-918. Published online October 2, 2018; DOI: https://doi.org/10.4143/crt.2018.314

Abstract PDF Supplementary Material PubReader ePub

Purpose
The purpose of this study was to determine whether histologic inflammation (HI) in initial and repeat prostate biopsy specimens was significantly associated with the detection of prostate cancer.
Materials and Methods
Between 2005 and 2017, the clinicopathological records of patients with high prostatespecific antigen (PSA) levels who underwent initial and repeat prostate biopsies were retrospectively reviewed. The presence of HI and its degree in each biopsied specimen were interpreted by one uropathologist with 20 years of experience. The association between HI and cancer diagnosis was statistically assessed, with p < 0.05 considered significant, and the cancer and non-cancer groups were compared.
Results
Among the 522 patients with a median PSA levels of 6.5 ng/dL, including 258 (49.4%) whose cancer was diagnosed following repeat biopsy, the median degrees of HI in the initial and repeat biopsies were 25.0% and 41.7%, respectively. Furthermore, 211 (40.4%) and 247 (47.3%) patients had HI (> 0%) on biopsied specimens, respectively. Comparison of the cancer and noncancer groups revealed that a greater rate of HI specimens in the initial biopsy was associated with fewer prostate cancer diagnoses following repeat biopsy (p < 0.001). Other comparisons between the cancer and non-cancer groups showed that the cancer group had a significantly higher rate of hypertension, whereas those non-cancer group had a significantly higher rate of benign prostatic hyperplasia and prostatitis (p < 0.05).
Conclusion
A finding of a lesser degree of HI in the initial and a greater degree of HI in the repeat biopsied specimens was associated with the higher probability of cancer diagnosis in patients with high PSA levels.

Citations

Citations to this article as recorded by

Growth and differentiation factor 15 and NF‐κB expression in benign prostatic biopsies and risk of subsequent prostate cancer detection
Benjamin A. Rybicki, Sudha M. Sadasivan, Yalei Chen, Oleksandr Kravtsov, Watchareepohn Palangmonthip, Kanika Arora, Nilesh S. Gupta, Sean Williamson, Kevin Bobbitt, Dhananjay A. Chitale, Deliang Tang, Andrew G. Rundle, Kenneth A. Iczkowski
Cancer Medicine.2021; 10(9): 3013. CrossRef

6,425 View
144 Download
1 Web of Science
1 Crossref

Second Primary Cancer Risk among Kidney Cancer Patients in Korea: A Population-Based Cohort Study: Jae Young Joung, Whi-An Kwon, Jiwon Lim, Chang-Mo Oh, Kyu-Won Jung, Sung Han Kim, Ho Kyung Seo, Weon Seo Park, Jinsoo Chung, Kang Hyun Lee, Young-Joo Won; Cancer Res Treat. 2018;50(1):293-301. Published online April 19, 2017; DOI: https://doi.org/10.4143/crt.2016.543

Abstract PDF Supplementary Material PubReader ePub

Purpose
Secondary primary cancers (SPCs) commonly arise in patients with renal cell carcinoma (RCC). We designed the present study to estimate the SPC incidence in Korean patients with RCC.
Materials and Methods
The study cohort was population-based and consisted of 40,347 individuals from the Korean Central Cancer Registry who were diagnosed with primary renal cancer between 1993 and 2013. Standardized incidence ratios (SIRs) for SPCs were estimated for different ages at diagnosis, latencies, diagnostic periods, and treatments.
Results
For patients with primary RCC, the risk of developing a SPC was higher than the risk of developing cancer in the general population (SIR, 1.13; 95% confidence interval, 1.08 to 1.18). Most cancer types showed higher incidences in patients with RCC than in the general population. However, the relative incidence of gastric cancer as an SPC varied by age. Gastric cancer incidence was elevated in young patients (< 30 years) with RCC, but reduced in older (≥ 30) patients with RCC. Patients with advanced RCC died prematurely, regardless of SPC development. In contrast, those with early-stage RCC survived for longer periods, although SPC development affected their post-RCC survival. After SPC development, women had better survival than men.
Conclusion
In Korean patients with primary RCC, the incidence of SPC was 13% higher than the incidence of cancer in the general population. These findings may play important roles in the conduct of follow-up evaluations and education for patients with RCC.

Citations

Citations to this article as recorded by

Next-generation sequencing identifies the mutational signature of double primary and metastatic malignancies: A case report
Shiying Tang, Yixiao Deng, Yinan Yan, Jie Bai, Huiying He, Shudong Zhang, Jie Yang, Min Qiu, Xiaojun Tian
Current Urology.2024;[Epub] CrossRef
Renal cell carcinoma and risk of second primary cancer: A Danish nationwide cohort study
Maria B. Bengtsen, Dóra K. Farkas, Henrik T. Sørensen, Mette Nørgaard
Cancer Medicine.2024;[Epub] CrossRef
Chance, ignorance, and the paradoxes of cancer: Richard Peto on developing preventative strategies under uncertainty
George Davey Smith, Albert Hofman, Paul Brennan
European Journal of Epidemiology.2023; 38(12): 1227. CrossRef
Better Prognosis and Survival in Esophageal Cancer Survivors After Comorbid Second Primary Malignancies: A SEER Database-Based Study
Jiayue Ye, Sheng Hu, Wenxiong Zhang, Deyuan Zhang, Yang Zhang, Dongliang Yu, Jinhua Peng, Jianjun Xu, Yiping Wei
Frontiers in Surgery.2022;[Epub] CrossRef
Effect of prior thyroid cancer on survival of primary liver cancer: a study based on the SEER database
Hong Liu, Xin Heng, Yuan Tian, Zhongming Yang
Scientific Reports.2022;[Epub] CrossRef
Being Precise About Precision Mental Health
Peter Szatmari, Ezra Susser
JAMA Psychiatry.2022; 79(12): 1149. CrossRef
Second Primary Cancers After Kidney Cancers, and Kidney Cancers as Second Primary Cancers
Guoqiao Zheng, Kristina Sundquist, Jan Sundquist, Tianhui Chen, Asta Försti, Otto Hemminki, Kari Hemminki
European Urology Open Science.2021; 24: 52. CrossRef
miR‐34a in extracellular vesicles from bone marrow mesenchymal stem cells reduces rheumatoid arthritis inflammation via the cyclin I/ATM/ATR/p53 axis
Huaiguo Wu, Xike Zhou, Xuedong Wang, Wei Cheng, Xinjia Hu, Yueping Wang, Bing Luo, Wenjun Huang, Juan Gu
Journal of Cellular and Molecular Medicine.2021; 25(4): 1896. CrossRef
Deciphering the Risk of Developing Second Primary Thyroid Cancer Following a Primary Malignancy—Who Is at the Greatest Risk?
Lily N. Trinh, Andrew R. Crawford, Mohammad H. Hussein, Mourad Zerfaoui, Eman A. Toraih, Gregory W. Randolph, Emad Kandil
Cancers.2021; 13(6): 1402. CrossRef
Significant current epidemiological trend: Haematological malignancies as subsequent primary tumours in cancer patients
Lucie Pehalova, Denisa Krejci, Jana Halamkova, Lenka Smardova, Lenka Snajdrova, Ladislav Dusek
Cancer Epidemiology.2021; 72: 101929. CrossRef
Prognosis of patients with axillary lymph node metastases from occult breast cancer: analysis of multicenter data
Haeyoung Kim, Won Park, Su SSan Kim, Sung Ja Ahn, Yong Bae Kim, Tae Hyun Kim, Jin Hee Kim, Jin-Hwa Choi, Hae Jin Park, Jee Suk Chang, Doo Ho Choi
Radiation Oncology Journal.2021; 39(2): 107. CrossRef
The Risk and Prognosis of Secondary Primary Malignancy in Lung Cancer: A Population-Based Study
Jia Hong, Rongrong Wei, Chuang Nie, Anastasiia Leonteva, Xu Han, Xinyu Du, Jing Wang, Lin Zhu, Wenjing Tian, Haibo Zhou
Future Oncology.2021; 17(33): 4497. CrossRef
Clear Cell Papillary Renal Cell Carcinoma Shares Distinct Molecular Characteristics and may be Significantly Associated With Higher Risk of Developing Second Primary Malignancy
Xi Tian, Wen-Hao Xu, Jun-Long Wu, Hua-Lei Gan, Hong-Kai Wang, Wei-Jie Gu, Yuan-Yuan Qu, Hai-Liang Zhang, Ding-Wei Ye
Pathology and Oncology Research.2021;[Epub] CrossRef
Primary Adenocarcinoma of Lung with Synchronous Renal Cell Carcinoma: A Case Report and Review of the Literature
Sharareh Seifi, Zahra Esfahani-Monfared, Mihan Pourabdollah, Sara Haseli
International Journal of Cancer Management.2020;[Epub] CrossRef
Second primary cancers in patients with oral cavity cancer included in the Korea Central Cancer Registry
Seung-Ki Min, Sung Weon Choi, Jiwon Lim, Joo Yong Park, Kyu-Won Jung, Young-Joo Won
Oral Oncology.2019; 95: 16. CrossRef
Post–Modern Epidemiology: When Methods Meet Matter
George Davey Smith
American Journal of Epidemiology.2019; 188(8): 1410. CrossRef
Prognosis of the Metachronous and Synchronous Bilateral Renal Cancer and Second Primary Cancer After the Bilateral Renal Cancer: a Population-Based Analysis
Mierxiati Abudurexiti, Jun Wang, Ning Shao, Fang-Ning Wan, Wen-Kai Zhu, Bo Dai, Yao Zhu, Ding-Wei Ye
SN Comprehensive Clinical Medicine.2019; 1(11): 900. CrossRef
Risk of second primary Cancer among bladder Cancer patients: a population-based cohort study in Korea
Whi-An Kwon, Jae Young Joung, Jiwon Lim, Chang-Mo Oh, Kyu-Won Jung, Sung Han Kim, Ho Kyung Seo, Weon Seo Park, Jinsoo Chung, Kang Hyun Lee, Young-Joo Won
BMC Cancer.2018;[Epub] CrossRef

11,972 View
271 Download
18 Web of Science
18 Crossref

Current Trends in the Incidence and Survival Rate of Urological Cancers in Korea: Jae Young Joung, Jiwon Lim, Chang-Mo Oh, Kyu-Won Jung, Hyunsoon Cho, Sung Han Kim, Ho Kyung Seo, Weon Seo Park, Jinsoo Chung, Kang Hyun Lee, Young-Joo Won; Cancer Res Treat. 2017;49(3):607-615. Published online September 23, 2016; DOI: https://doi.org/10.4143/crt.2016.139

Abstract PDF Supplementary Material PubReader ePub

Purpose
This descriptive study assessed the current trends in the incidence of urological cancers and patient survival in Korea.
Materials and Methods
In this nationwide retrospective observational study based on the data from the Korea National Cancer Incidence Database (KNCIDB), this study analyzed the age-standardized incidence rates (ASRs) and annual percentage changes (APCs) of kidney, bladder, prostate, testicular, and penile cancers as well as cancer of the renal pelvis and ureter between 1999 and 2012. The relative survival rates (RSRs) were calculated for urological cancer patients diagnosed between 1993 and 2012 from the KNCIDB data.
Results
Prostate cancer was diagnosed in 66,812 individuals followed by bladder (41,549) and kidney (36,836) cancers. The overall ASR (18.26 per 100,000) increased with age because of the higher ASRs of bladder and prostate cancers in the elderly. The ASR for kidney cancer was highest in the 40-59-year-old group, whereas testicular cancer occurred most frequently before the age of 40. The incidence of most urological cancers increased (overall APC, 6.39%; p < 0.001), except for penile (APC, –2.01%; p=0.05) and bladder (APC, –0.40%; p=0.25) cancers. The overall survival increased steadily (5-year RSR, 66.4% in 1993-1995 vs. 84.2% in 2008-2012; p < 0.001), particularly for prostate (by 34.10%) and kidney (by 16.30%) cancers, but not for renal pelvis and ureter cancers (–7.20%).
Conclusion
The most common urological cancer in Korea was prostate cancer followed by bladder and kidney cancers. The incidence of most urological cancers, except for penile and bladder cancers, increased. Survival also increased, particularly for prostate and kidney cancers.

Citations

Citations to this article as recorded by

Twenty-two-year incidence trend of urological cancers in the Republic of Korea: 1999–2020
Seunghyeon Cho, Won-Ju Park
Investigative and Clinical Urology.2024; 65(1): 23. CrossRef
Risk Factors Associated with Urothelial Bladder Cancer
Souhail Alouini
International Journal of Environmental Research and Public Health.2024; 21(7): 954. CrossRef
Optimal sequencing of the first- and second-line target therapies in metastatic renal cell carcinoma: based on nationally representative data analysis from the Korean National Health Insurance System
Dong Hyuk Kang, Joo Yong Lee, Yunhee Lee, U-Syn Ha
BMC Cancer.2023;[Epub] CrossRef
Empowerment-Based Education in Urological Patients: A Scoping Review
Giulia Villa, Emanuele Galli, Vittoria Azzimonti, Marianna Doneda, Noemi Giannetta, Duilio Fiorenzo Manara
Clinical Nursing Research.2022; 31(4): 666. CrossRef
Incidence and mortality projections for major cancers among Korean men until 2034, with a focus on prostate cancer
Sahyun Pak, Kyu-Won Jung, Eun-Hye Park, Young Hwii Ko, Young-Joo Won, Jae Young Joung
Investigative and Clinical Urology.2022; 63(2): 175. CrossRef
MicroRNA Signatures in the Upper Urinary Tract Urothelial Carcinoma Scenario: Ready for the Game Changer?
Alessandra Cinque, Anna Capasso, Riccardo Vago, Matteo Floris, Michael W. Lee, Roberto Minnei, Francesco Trevisani
International Journal of Molecular Sciences.2022; 23(5): 2602. CrossRef
Trends of First-Line Targeted Therapy in Korean Patients With Metastatic Clear Cell Renal Cell Carcinoma: Sunitinib Versus Pazopanib, a Multicenter Study
Minsu Choi, Teak Jun Shin, Byung Hoon Kim, Chun Il Kim, Kyung Seop Lee, Seock Hwan Choi, Hyun Tae Kim, Tae-Hwan Kim, Tae Gyun Kwon, Young Hwii Ko, Yoon Soo Hah, Jae-Shin Park, Se Yun Kwon
The Korean Journal of Urological Oncology.2022; 20(2): 115. CrossRef
The association between pain intensity and disability in patients with failed back surgery syndrome, treated with spinal cord stimulation
Mats De Jaeger, Lisa Goudman, Sam Eldabe, Robert Van Dongen, Ann De Smedt, Maarten Moens
Disability and Rehabilitation.2021; 43(15): 2157. CrossRef
Rapid recurrence of squamous cell carcinoma at a lymphocele after nephroureterectomy: A rare case report
Kosuke Ogawa, Yousuke Shimizu, Shoko Uketa, Noriaki Utsunomiya, Satsuki Asai, Misa Ishihara, Kimio Hashimoto, Sojun Kanamaru
IJU Case Reports.2021; 4(2): 118. CrossRef
Survival and Characteristics of Bladder Cancer: Analysis of the Malaysian National Cancer Registry
Mohd Nasrullah Nik Ab Kadir, Suhaily Mohd Hairon, Najib Majdi Yaacob, Azizah Ab Manan, Nabihah Ali
International Journal of Environmental Research and Public Health.2021; 18(10): 5237. CrossRef
The incidence and prevalence of upper tract urothelial carcinoma: a systematic review
Ahmed Soualhi, Elke Rammant, Gincy George, Beth Russell, Deborah Enting, Rajesh Nair, Mieke Van Hemelrijck, Cecilia Bosco
BMC Urology.2021;[Epub] CrossRef
Impact of chemotherapy on subsequent generations
Biren V. Patel, James M. Hotaling
Urologic Oncology: Seminars and Original Investigations.2020; 38(1): 10. CrossRef
Financial toxicity and its associations with health-related quality of life among urologic cancer patients in an upper middle-income country
Chuo Yew Ting, Guan Chou Teh, Kong Leong Yu, Haridah Alias, Hui Meng Tan, Li Ping Wong
Supportive Care in Cancer.2020; 28(4): 1703. CrossRef
Time Trends for Prostate Cancer Incidence from 2003 to 2013 in South Korea: An Age-Period-Cohort Analysis
Hyun Young Lee, Do Kyoung Kim, Seung Whan Doo, Won Jae Yang, Yun Seob Song, Bora Lee, Jae Heon Kim
Cancer Research and Treatment.2020; 52(1): 301. CrossRef
Anesthetic considerations for urologic surgeries
Chang-Hoon Koo, Jung-Hee Ryu
Korean Journal of Anesthesiology.2020; 73(2): 92. CrossRef
Emergency room imaging in patients with genitourinary cancers: analysis of the spectrum of CT findings and their relation to patient outcomes
Sungmin Woo, Jad Bou Ayache, Peter Sawan, Julian Infantino, Natalie Gangai, Andreas Wibmer, Hedvig Hricak, Jeffrey S. Groeger, Hebert Alberto Vargas
Emergency Radiology.2020; 27(4): 413. CrossRef
Detection of Incidental Prostate Cancer or Urothelial Carcinoma Extension in Urinary Bladder Cancer Patients by Using Multiparametric MRI: A Retrospective Study Using Prostate Imaging Reporting and Data System Version 2.0
Sang Eun Yoon, Byung Chul Kang, Hyun-Hae Cho, Sanghui Park
Journal of the Korean Society of Radiology.2020; 81(3): 610. CrossRef
Health-Related Quality of Life, Perceived Social Support, and Depression in Disease-Free Survivors Who Underwent Curative Surgery Only for Prostate, Kidney and Bladder Cancer: Comparison among Survivors and with the General Population
Dong Wook Shin, Hyun Sik Park, Sang Hyub Lee, Seung Hyun Jeon, Seok Cho, Seok Ho Kang, Seung Chol Park, Jong Hyock Park, Jinsung Park
Cancer Research and Treatment.2019; 51(1): 289. CrossRef
Synchronous Bilateral RCC Is Associated With Poor Recurrence-Free Survival Compared With Unilateral RCC: A Single-Center Study With Propensity Score Matching Analysis
Jung Kwon Kim, Hakmin Lee, Jong Jin Oh, Sangchul Lee, Sung Kyu Hong, Sang Eun Lee, Seok-Soo Byun
Clinical Genitourinary Cancer.2019; 17(3): e570. CrossRef
Application of the International Metastatic Renal Cell Carcinoma Database Consortium and Memorial Sloan Kettering Cancer Center Risk Models in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma: A Multi-Institutional Retrospective Study Using th
Jung Kwon Kim, Sung Han Kim, Mi Kyung Song, Jungnam Joo, Seong Il Seo, Cheol Kwak, Chang Wook Jeong, Cheryn Song, Eu Chang Hwang, Ill Young Seo, Hakmin Lee, Sung-Hoo Hong, Jae Young Park, Jinsoo Chung
Cancer Research and Treatment.2019; 51(2): 758. CrossRef
Trends in clinical, operative, and pathologic characteristics of surgically treated renal mass in a Korean center: A surgical series from 1988 through 2015
Ho Won Kang, Sung Pil Seo, Won Tae Kim, Seok Joong Yun, Sang-Cheol Lee, Wun-Jae Kim, Eu Chang Hwang, Seok Ho Kang, Sung-Hoo Hong, Jinsoo Chung, Tae Gyun Kwon, Hyeon Hoe Kim, Cheol Kwak, Seok-Soo Byun, Yong-June Kim
Investigative and Clinical Urology.2019; 60(3): 184. CrossRef
Survival and clinical prognostic factors in metastatic non‐clear cell renal cell carcinoma treated with targeted therapy: A multi‐institutional, retrospective study using the Korean metastatic renal cell carcinoma registry
Jung Kwon Kim, Sung Han Kim, Mi Kyung Song, Jungnam Joo, Seong Il Seo, Cheol Kwak, Chang Wook Jeong, Cheryn Song, Eu Chang Hwang, Ill Young Seo, Hakmin Lee, Sung‐Hoo Hong, Jae Young Park, Jinsoo Chung
Cancer Medicine.2019; 8(7): 3401. CrossRef
The Prognostic Significance of Protein Expression of CASZ1 in Clear Cell Renal Cell Carcinoma
Bohyun Kim, Minsun Jung, Kyung Chul Moon
Disease Markers.2019; 2019: 1. CrossRef
History of Diabetes Mellitus and Risk of Prostate Cancer: A Meta-Epidemiological Study of Population-Based Cohort Studies in East Asian Men
Jong-Myon Bae
The Korean Journal of Urological Oncology.2019; 17(3): 119. CrossRef
Development and Validation of the Korean Version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients with Non-muscle Invasive Bladder Cancer: EORTC QLQ-NMIBC24
Jinsung Park, Dong Wook Shin, Tae-Hwan Kim, Seung Il Jung, Jong Kil Nam, Seung Chol Park, Sungwoo Hong, Jae Hung Jung, Hongwook Kim, Won Tae Kim
Cancer Research and Treatment.2018; 50(1): 40. CrossRef
Rate and association of lower urinary tract infection with recurrence after transurethral resection of bladder tumor
Byung Soo Kim, Bum Sik Tae, Ja Hyeon Ku, Cheol Kwak, Hyeon Hoe Kim, Chang Wook Jeong
Investigative and Clinical Urology.2018; 59(1): 10. CrossRef
Detection and recurrence rate of transurethral resection of bladder tumors by narrow-band imaging: Prospective, randomized comparison with white light cystoscopy
Seung Bin Kim, Sung Goo Yoon, Jonghyun Tae, Jae Yoon Kim, Ji Sung Shim, Sung Gu Kang, Jun Cheon, Jeong Gu Lee, Je Jong Kim, Seok Ho Kang
Investigative and Clinical Urology.2018; 59(2): 98. CrossRef
Significance of Intratumoral Fibrosis in Clear Cell Renal Cell Carcinoma
Jae Won Joung, Hoon Kyu Oh, Sun Jae Lee, Young Ah Kim, Hyun Jin Jung
Journal of Pathology and Translational Medicine.2018; 52(5): 323. CrossRef
Yes-Associated Protein Expression Is Correlated to the Differentiation of Prostate Adenocarcinoma
Myung-Giun Noh, Sung Sun Kim, Eu Chang Hwang, Dong Deuk Kwon, Chan Choi
Journal of Pathology and Translational Medicine.2017; 51(4): 365. CrossRef

13,062 View
265 Download
24 Web of Science
29 Crossref

Systemic Treatments for Metastatic Renal Cell Carcinoma: 10-Year Experience of Immunotherapy and Targeted Therapy: Sung Han Kim, Weon Seo Park, Sun Ho Kim, Jae Young Joung, Ho Kyung Seo, Kang Hyun Lee, Jinsoo Chung; Cancer Res Treat. 2016;48(3):1092-1101. Published online January 28, 2016; DOI: https://doi.org/10.4143/crt.2015.316

Abstract PDF PubReader ePub

Purpose
The purpose of this study is to compare the outcomes of first-line systemic targeted therapy (TT) and immunotherapy (IT) in patients with metastatic renal cell carcinoma (mRCC).
Materials and Methods
This study was a retrospective review of the data of 262 patients treated with systemic IT or TT with tyrosine kinase inhibitors between 2003 and 2013. The objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) were assessed using Response Evaluation Criteria in Solid Tumor ver. 1.0 criteria and the Kaplan-Meier method with log-rank test.
Results
During the median 4.3-month treatment and the 24-month follow-up period, the ORR/PFS/OS of the overall first-line and second-line therapy were 41.9%/8.1 months/16.8 months and 27.5%/6.5 months/15.3 months, respectively. The first-line TT/IT/sequential IT had a PFS of 9.3/6.4/5.7 months and an OS of 15.8/16.5/40.6 months (all p < 0.05). The second-line of TT/IT had a PFS of 7.1/2.1 months (both p < 0.05) and an OS of 16.6/8.6 months (p=0.636), respectively. Pazopanib provided the best median PFS of 11.0 months (p < 0.001) and a quadruple IT regimen had a superior PFS (p=0.522). For OS, sequential treatment with IT and TT was superior compared to treatment with either IT or TT alone (40.6/16.5/15.8 months, p=0.014). The prognosis according to the Memorial Sloan Kettering Cancer Center model showed that favorable/intermediate/poor risk groups had a PFS of 8.5/10.4/2.3 months, and an OS of 43.1/20.4/5.6 months, respectively. The prognosis calculated using the Heng model showed that the favorable/intermediate/poor risk groups had a PFS of 9.2/3.9/2.7 months, and an OS of 32.4/16.5/6.1months, respectively (all p < 0.001).
Conclusion
In patients with mRCC, TT provided a better PFS and OS compared with IT.

Citations

Citations to this article as recorded by

Optimal sequencing of the first- and second-line target therapies in metastatic renal cell carcinoma: based on nationally representative data analysis from the Korean National Health Insurance System
Dong Hyuk Kang, Joo Yong Lee, Yunhee Lee, U-Syn Ha
BMC Cancer.2023;[Epub] CrossRef
Adenovirus vaccine therapy with CD137L promotes CD8+ DCs-mediated multifunctional CD8+ T cell immunity and elicits potent anti-tumor activity
Jiage Ding, Nan Jiang, Yanyan Zheng, Jiawei Wang, Lin Fang, Huizhong Li, Jie Yang, Ankang Hu, Pengli Xiao, Qing Zhang, Dafei Chai, Junnian Zheng, Gang Wang
Pharmacological Research.2022; 175: 106034. CrossRef
Skeletal Muscle Metastasis From Renal Cell Carcinoma: A Case Series and Literature Review
Juan Sun, Zimu Zhang, Yu Xiao, Hanzhong Li, Zhigang Ji, Penghu Lian, Xuebin Zhang
Frontiers in Surgery.2022;[Epub] CrossRef
Impact of Metastasectomy on Cancer Specific and Overall Survival in Metastatic Renal Cell Carcinoma: Analysis of the REMARCC Registry
Margaret F. Meagher, Maria C Mir, Riccardo Autorino, Andrea Minervini, Maximilian Kriegmair, Tobias Maurer, Francesco Porpiglia, Siska Van Bruwaene, Estefania Linares, Vital Hevia, Mireia Musquera, Eduard Roussel, Nicola Pavan, Alessandro Antonelli, Shudo
Clinical Genitourinary Cancer.2022; 20(4): 326. CrossRef
Comparison of prognostic factors that affect the survival of patients with metachronous and synchronous metastases of renal cell carcinoma
D. V. Semenov, R. V. Orlova, V. I. Shirokorad, S. V. Kostritsky, S. G. Grigoriev, Yu. S. Korneva
Urology Herald.2022; 10(3): 65. CrossRef
Co‐immunization with L‐Myc enhances CD8+ or CD103+ DCs mediated tumor‐specific multi‐functional CD8+ T cell responses
Dafei Chai, Zichun Zhang, Nan Jiang, Jiage Ding, Dong Qiu, Shang Yuchen Shi, Gang Wang, Lin Fang, Huizhong Li, Hui Tian, Jie Yang, Qing Zhang, Junnian Zheng
Cancer Science.2021; 112(9): 3469. CrossRef
Survival prognoses of Heng intermediate-risk patients with metastatic renal cell carcinoma treated with immunotherapy or targeted therapy: A real-world, single-center retrospective study
Sung Han Kim, Dong-Eun Lee, Jae Young Joung, Ho Kyung Seo, Kang Hyun Lee, Jinsoo Chung
Investigative and Clinical Urology.2020; 61(2): 146. CrossRef
Apatinib as targeted therapy for advanced bone and soft tissue sarcoma: a dilemma of reversing multidrug resistance while suffering drug resistance itself
Qian-Kun Yang, Tong Chen, Shi-Qi Wang, Xiao-Jing Zhang, Zhong-Xiang Yao
Angiogenesis.2020; 23(3): 279. CrossRef
Surgical-only treatment of pancreatic and extra-pancreatic metastases from renal cell carcinoma - quality of life and survival analysis
Stefania Brozzetti, Simone Bini, Nelide De Lio, Carlo Lombardo, Ugo Boggi
BMC Surgery.2020;[Epub] CrossRef
Liver metastasis and Heng risk are prognostic factors in patients with non-nephrectomized synchronous metastatic renal cell carcinoma treated with systemic therapy
Sung Han Kim, Jung Kwon Kim, Eun Young Park, Jungnam Joo, Kang Hyun Lee, Ho Kyung Seo, Jae Young Joung, Jinsoo Chung, Aamir Ahmad
PLOS ONE.2019; 14(2): e0211105. CrossRef
A Retrospective Analysis of the Impact of Metastasectomy on Prognostic Survival According to Metastatic Organs in Patients With Metastatic Renal Cell Carcinoma
Sung Han Kim, Weon Seo Park, Boram Park, Sahyun Pak, Jinsoo Chung
Frontiers in Oncology.2019;[Epub] CrossRef
Survival of patients receiving systematic therapy for metachronous or synchronous metastatic renal cell carcinoma: a retrospective analysis
Sung Han Kim, Dong-eun Lee, Boram Park, Jungnam Joo, Jae Young Joung, Ho Kyung Seo, Kang Hyun Lee, Jinsoo Chung
BMC Cancer.2019;[Epub] CrossRef
Prognostic significance of nephrectomy in metastatic renal cell carcinoma treated with systemic cytokine or targeted therapy: A 16-year retrospective analysis
Sung Han Kim, Kyung-Chae Jeong, Jae Young Joung, Ho Kyung Seo, Kang Hyun Lee, Jinsoo Chung
Scientific Reports.2018;[Epub] CrossRef
The effect of a gene associated with retinoid-interferon-induced mortality 19 (GRIM-19) on STAT3-induced gene expression in renal carcinoma
Lingang Cui, Qingjun Meng, Jianguo Wen, Zechen Yan, Zhan Gao, Yudong Tian, Pengchao Xu, Pengchao Lian, Haizhou Yu
The Journal of Biochemistry.2018; 164(4): 285. CrossRef
The Experience of Uncertainty in Cancer Patients Undergoing Chemotherapy
Yoon Sun Kim, Young Sook Tae, Keum Hee Nam, Heui Yeoung Kim
Asian Oncology Nursing.2018; 18(3): 115. CrossRef
Suppression of homology-dependent DNA double-strand break repair induces PARP inhibitor sensitivity inVHL-deficient human renal cell carcinoma
Susan E. Scanlon, Denise C. Hegan, Parker L. Sulkowski, Peter M. Glazer
Oncotarget.2018; 9(4): 4647. CrossRef
Uncharacteristic metastasis of a renal clear-cell carcinoma to the muscles of the forearm—case report
Oliwia Kozak, Paweł Turzyński, Karolina Markiet, Joanna Pieńkowska, Katarzyna Skrobisz-Balandowska, Michał Studniarek
BJR|case reports.2017; 3(3): 20150495. CrossRef
LncRNA RP11-436H11.5, functioning as a competitive endogenous RNA, upregulates BCL-W expression by sponging miR-335-5p and promotes proliferation and invasion in renal cell carcinoma
Kefeng Wang, Wei Jin, Yan Song, Xiang Fei
Molecular Cancer.2017;[Epub] CrossRef
Anti-angiogenesis target therapy for advanced osteosarcoma
Lu Xie, Tao Ji, Wei Guo
Oncology Reports.2017; 38(2): 625. CrossRef
A retrospective comparative study of progression-free survival and overall survival between metachronous and synchronous metastatic renal cell carcinoma in intermediate- or poor-risk patients treated with VEGF-targeted therapy
Sung Han Kim, Yoon Seok Suh, Dong-Eun Lee, Boram Park, Jungnam Joo, Jae Young Joung, Ho Kyung Seo, Kang Hyun Lee, Jinsoo Chung
Oncotarget.2017; 8(55): 93633. CrossRef
Survival outcomes of double- and triple-sequential targeted therapy in patients with metastatic renal cell carcinoma: a retrospective comparison
Sung Han Kim, Yoon Seok Suh, Jung Kwon Kim, Jae Young Joung, Ho Kyung Seo, Kang Hyun Lee, Jinsoo Chung
Oncotarget.2017; 8(59): 100056. CrossRef
Introducing, OncoTarget
Mikhail Blagosklonny, Andrei Gudkov
Oncotarget.2010; 1(1): 2. CrossRef
Introducing, OncoTarget
Mikhail Blagosklonny, Andrei Gudkov
Oncotarget.2010; 1(1): 2. CrossRef

12,325 View
172 Download
22 Web of Science
23 Crossref

Case Report

A Case Report of Partial Nephrectomy of Mucinous Cystadenocarcinoma in Kidney and Its Literature Review: Sung Han Kim, Heong Dong Yuk, Weon Seo Park, Sun Ho Kim, Jae Young Joung, Ho Kyung Seo, Kang Hyun Lee, Jinsoo Chung; Cancer Res Treat. 2016;48(2):838-842. Published online February 13, 2015; DOI: https://doi.org/10.4143/crt.2014.219

Abstract PDF PubReader ePub

Mucinous cystadenocarcinoma (MC) of the kidney is a rare epithelial tumor originating from the renal pelvic urothelium and few study cases have been reported. Because of the rarity of these tumors and their unknown histogenesis, its diagnosis is difficult until surgical exploration. We report here on a 55-year-old man referred to the urology department from the hepatology department because of a cystic renal mass measuring approximately 5 cm in size, which was detected incidentally under ultrasonography during the routine examination of liver. The renal mass was finally diagnosed as MC originating from kidney after partial nephrectomy and the patient still showed no evidence of recurrence until 12 months postoperatively. This is the first report on a case of renal MC in a patient who underwent partial nephrectomy. The aim of this report is to present our unusual case of MC and also review the previous literature on the pathological and radiological aspects of MC of kidney.

Citations

Citations to this article as recorded by

Mucinous adenocarcinoma in kidneys with developmental anomalies - a report of two cases
Kasi Viswanath Gali, Arun Chawla, K. R. Surag, Sunil Pillai Bhaskara, Padmaraj Hegde
BMC Urology.2024;[Epub] CrossRef
Case report and literature review: Robot-assisted laparoscopic left renal mucinous cystadenocarcinoma radical nephrectomy
Zikuan Ning, Haoxun Zhang, Bowen Wang, Yingwei Wang, Yiwen Liu, Boju Tao, Guoling Zhang, Hua Liu, Chunyang Wang
Frontiers in Surgery.2023;[Epub] CrossRef
Mucinous cystadenocarcinoma in the renal pelvis: primary or secondary? Case report and literature review
An Tamsin, Charlotte Schillebeeckx, Charlotte Van Langenhove, Kathy Vander Eeckt, Dieter Ost, Kevin Wetzels
Acta Chirurgica Belgica.2020; 120(6): 417. CrossRef

24,383 View
121 Download
6 Web of Science
3 Crossref

Original Articles

Bcl-2 as a Predictive Factor for Biochemical Recurrence after Radical Prostatectomy: An Interim Analysis: In-Chang Cho, Han Soo Chung, Kang Su Cho, Jeong Eun Kim, Jae Young Joung, Ho Kyung Seo, Jinsoo Chung, Weon Seo Park, Eun Kyung Hong, Kang Hyun Lee; Cancer Res Treat. 2010;42(3):157-162. Published online September 30, 2010; DOI: https://doi.org/10.4143/crt.2010.42.3.157

Abstract PDF PubReader ePub

Purpose

The objective of this study was to determine Bcl-2 expression in localized prostate cancer and its potential role as a predictive factor for biochemical recurrence (BCR).

Materials and Methods

This study included 171 Korean patients with newly diagnosed adenocarcinoma of the prostate who underwent radical prostatectomy (RP) without neoadjuvant therapy at a single center between February 2005 and May 2009. RP specimens obtained from these patients were analyzed for the expression of Bcl-2 using tissue microarray. The values of Bcl-2 and other clinicopathologic factors were evaluated. Statistical analysis was performed with contingency table analysis, chi-square tests, and a Cox proportional hazard model.

Results

Bcl-2 expression was immunohistologically-confirmed in 42 patients (24.6%). Bcl-2 expression was not associated with conventional clinicopathologic factors. Bcl-2 negative patients had a significantly longer mean BCR-free survival than Bcl-2-positive patients (p=0.036). Among several variables, a high Gleason score in the RP specimen (≥8), extraprostatic extension, seminal vesicle invasion (SVI), lymphovascular invasion (LVI), and Bcl-2 expression were significant predictors of BCR based on univariate analysis. Multivariate Cox proportional hazards analysis revealed that BCR was significantly associated with a high prostate specific antigen level (p=0.047), SVI (p<0.001), a positive surgical margin (p=0.004) and Bcl-2 expression (p=0.012).

Conclusion

Bcl-2 expression in RP specimens is associated with a significantly worse outcome, suggesting a potential clinical role for Bcl-2. Post-operative Bcl-2 could be a significant predictor of outcome after RP.

Citations

Citations to this article as recorded by

Association of Lymphovascular Invasion with Biochemical Recurrence and Adverse Pathological Characteristics of Prostate Cancer: A Systematic Review and Meta-analysis
Jakub Karwacki, Marcel Stodolak, Andrzej Dłubak, Łukasz Nowak, Adam Gurwin, Kamil Kowalczyk, Paweł Kiełb, Nazar Holdun, Wojciech Szlasa, Wojciech Krajewski, Agnieszka Hałoń, Anna Karwacka, Tomasz Szydełko, Bartosz Małkiewicz
European Urology Open Science.2024; 69: 112. CrossRef
Immunohistochemical Expression of MDM2, Bcl-2, SATB2 and Ki-67 in Histological Variants of Unicystic Ameloblastoma
Koustubh Amol Surana, Deepak Pandiar, Reshma Poothakulath Krishnan
Head and Neck Pathology.2024;[Epub] CrossRef
Targeting the Intrinsic Apoptosis Pathway: A Window of Opportunity for Prostate Cancer
Daniel Westaby, Juan M. Jimenez-Vacas, Ana Padilha, Andreas Varkaris, Steven P. Balk, Johann S. de Bono, Adam Sharp
Cancers.2021; 14(1): 51. CrossRef
miR-205: A Potential Biomedicine for Cancer Therapy
Neeraj Chauhan, Anupam Dhasmana, Meena Jaggi, Subhash C. Chauhan, Murali M. Yallapu
Cells.2020; 9(9): 1957. CrossRef
Bcl‐2 is a prognostic marker and its silencing inhibits recurrence in ameloblastomas
Jue Young Kim, Jinsun Kim, Shadavlonjid Bazarsad, In‐Ho Cha, Sung‐Won Cho, Jin Kim
Oral Diseases.2019; 25(4): 1158. CrossRef
Tumor-Specific Induction of the Intrinsic Apoptotic Pathway—A New Therapeutic Option for Advanced Prostate Cancer?
Philipp Wolf
Frontiers in Oncology.2019;[Epub] CrossRef
PI3K pathway and Bcl-2 family. Clinicopathological features in prostate cancer
Norelia Torrealba, Gonzalo Rodriguez-Berriguete, Benito Fraile, Gabriel Olmedilla, Pilar Martínez-Onsurbe, Manuel Sánchez-Chapado, Ricardo Paniagua, Mar Royuela
The Aging Male.2018; 21(3): 211. CrossRef
Positive surgical margin is associated with biochemical recurrence risk following radical prostatectomy: a meta-analysis from high-quality retrospective cohort studies
Lijin Zhang, Bin Wu, Zhenlei Zha, Hu Zhao, Yuefang Jiang, Jun Yuan
World Journal of Surgical Oncology.2018;[Epub] CrossRef
The impact of lymphovascular invasion in patients with prostate cancer following radical prostatectomy and its association with their clinicopathological features
Wei Jiang, Lijin Zhang, Bin Wu, Zhenlei Zha, Hu Zhao, Yuan Jun, Yuefang Jiang
Medicine.2018; 97(49): e13537. CrossRef
Bcl2 en cáncer avanzado de próstata y asociación con resistencia a la castración
R.F. Velázquez-Macías, F.E. De La Torre-Rendón, G. Ramos-Rodríguez, C.A. Calzada-Mendoza, R.M. Coral-Vázquez
Revista Mexicana de Urología.2016; 76(5): 288. CrossRef
Application of a new technique, spiral tissue microarrays constructed using needle biopsy specimens, to prostate cancer research
AKIRA KOMIYA, TOMONORI KATO, TAKASHI HORI, JUNYA FUKUOKA, KENJI YASUDA, HIDEKI FUSE
International Journal of Oncology.2014; 44(1): 195. CrossRef
MicroRNA-205, a novel regulator of the anti-apoptotic protein Bcl2, is downregulated in prostate cancer
BERLINDA VERDOODT, MATTHIAS NEID, MARKUS VOGT, VIKTORIA KUHN, SVEN-THORSTEN LIFFERS, REIN-JÜRI PALISAAR, JOACHIM NOLDUS, ANDREA TANNAPFEL, ALIREZA MIRMOHAMMADSADEGH
International Journal of Oncology.2013; 43(1): 307. CrossRef

9,462 View
61 Download
12 Crossref

Invasive Thymoma Metastasizing to Supraclavicular Lymph Node - A case report -: Weon Seo Park, Kyeong Cheon Jung, Chul Woo Kim, Seong Hoe Park; J Korean Cancer Assoc. 1994;26(4):650-657.

Abstract PDF: Malignant thymoma is classified into two groups as type I and II according to the clinical features and histologic characteristics. The type I malignant thymoma is called as invasive thymoma and this group of thymoma can invade to mediastinum, lung and cervical lymph node. The type II malignant thymoma is known as thymic carcinoma and categorized inta true malignant tumor which can metastssize to distant organs. However, new disease entity well differentiated thymic carcinoma" was established by some authors based on the histologic features. We have recently experienced a case of invasive thymoma which metastasized to supraclavicular lymph node. The histologic findings of this case showed the same features of well differentiated thymic carcinoma described previously. We report this case with emphasis to pathological examination and immunohistologic characteristics. A 46-year-old male patient admitted because of recurrent and combined pneumonia. Norcardia, pseudomonas, acinetobacter, and Staphylococcus:cus aureus were found in the pleural effusion and sputum. The pneumonic consolidation was found in both lung field and empyema was noted in the left lung field. Multiple lymph nodes were palpable in the left supraclavicular areas. Biopsy was done with the clinical impression of malignancy. Two lymph nodes were excised, measuring 1.0 cm and 0.8 cm respectively. Microscopica11y thge lymph node was replaced with lobulated mass composed of epithelial cells and lymphocytes. The epithelial cells were round to ovoid and had small round eosinophilic and prominent nucleoli. Perivascular palisadng and perivascular spaces, which was described as organoid differentiation of well differentiated thymic carcinoma, were frequently found. The epithelial components were positive to CAM 5.2(anti-cytokeratin antibody). The lymphocytes were positive to JLl and CD45RO, and negative to CD45RB and L26(CD20, pan-B). In conclusion, the tumor showed features of thymoma histologically and immunohistocbemically. Later, it was proved that the patient had experienced thymectomy due to myasthenia gravis six years ago. The pathological features of the excised thymoma were aame as metastatic supraclavicular mass. We conclude that careful examination to search for capsular invasion is needed in thymoma to rule out invasive thymoma. Additionally, anti-JLI monoclonal antibody is useful for the diagnosis of the thymoma, since it is expressed only in the immature cortical thymocytes.

2,730 View
18 Download

First
Prev
Page of 1
Next
Last

Search